Latest News

Lupin partners with Abbvie to develop and commercialize new targeted oncology treatments

Pharma major Lupin Limited and global biopharmaceutical company AbbVie Inc., today announced that AbbVie has licensed Lupin’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.

Source link

Related posts

Does Male Menopause Exist?


STAT Plus: Ohio Medicaid cancels contracts with two big PBMs over ‘spread’ pricing


Prompt and non-prompt J/ ψ elliptic flow in Pb+Pb collisions at √sNN=5.02 Tev with the ATLAS detector


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy